2020
A systematic review of ketamine for the treatment of depression among older adults
Gupta A, Dhar R, Patadia P, Funaro M, Bhattacharya G, Farheen SA, Tampi RR. A systematic review of ketamine for the treatment of depression among older adults. International Psychogeriatrics 2020, 33: 179-191. PMID: 32600480, DOI: 10.1017/s1041610220000903.Peer-Reviewed Educational MaterialsConceptsUse of ketaminePrimary outcome measureTreatment of depressionOlder adultsAdverse effectsOutcome measuresMontgomery-Asberg Depression Rating Scale scoreDepression Rating Scale scoresBenefits of ketamineCognitive adverse effectsRating Scale scoresEsketamine groupPlacebo groupRemission rateIntranasal ketamineKetamine administrationMADRS scoresInclusion criteriaDepressive symptomsCurrent evidenceScale scoreDepression symptomsKetamineSystematic reviewNegative trials
2019
Increased ventromedial prefrontal cortex activity and connectivity predict poor sertraline treatment outcome in late‐life depression
Emam H, Steffens DC, Pearlson G, Wang L. Increased ventromedial prefrontal cortex activity and connectivity predict poor sertraline treatment outcome in late‐life depression. International Journal Of Geriatric Psychiatry 2019, 34: 730-737. PMID: 30761621, PMCID: PMC6480406, DOI: 10.1002/gps.5079.Peer-Reviewed Original ResearchConceptsLate-life depressionSelective serotonin reuptake inhibitorsNonresponder groupFunctional connectivitySSRI responseMADRS scoresResting-state functional magnetic resonance imaging (fMRI) scansMontgomery-Åsberg Depression Rating ScaleMajor depressive disorder patientsPrefrontal cortexMagnetic resonance imaging (MRI) scansFunctional magnetic resonance imaging (fMRI) scansSubgenual cingulate areaSerotonin reuptake inhibitorsDepressive disorder patientsAcute treatment responseResonance imaging scansDepression Rating ScaleLower functional connectivityHigher functional connectivityFalse discovery rate correctionResting-state activityDefault mode networkROI connectivityAntidepressant treatment
2012
Bupropion pre-treatment of endotoxin-induced depressive symptoms
DellaGioia N, Devine L, Pittman B, Hannestad J. Bupropion pre-treatment of endotoxin-induced depressive symptoms. Brain Behavior And Immunity 2012, 31: 197-204. PMID: 23064079, DOI: 10.1016/j.bbi.2012.10.008.Peer-Reviewed Original ResearchConceptsVisual analog scaleInflammatory cytokinesDepressive symptomsSerum levelsMontgomery-Åsberg Depression Rating ScaleSerotonin reuptake inhibitor citalopramLow-dose lipopolysaccharideReuptake inhibitor citalopramCross-over studyDepression Rating ScaleTotal MADRS scoreDopamine reuptake inhibitorInnate immune responseInnate immune systemIntravenous LPSLPS administrationReuptake inhibitorsAnalog scaleMADRS scoresHealthy subjectsImmune responseBupropionImmune systemCytokinesLPS
2005
Hippocampal Volume as a Predictor of Short-Term ECT Outcomes in Older Patients With Depression
Lekwauwa R, McQuoid D, Steffens D. Hippocampal Volume as a Predictor of Short-Term ECT Outcomes in Older Patients With Depression. American Journal Of Geriatric Psychiatry 2005, 13: 910-913. PMID: 16223970, DOI: 10.1097/00019442-200510000-00011.Peer-Reviewed Original ResearchConceptsHippocampal volumeMADRS scoresMontgomery-Asberg Depression Rating Scale scoreLarger right hippocampal volumesDepression Rating Scale scoresBaseline MADRS scoreRight hippocampal volumeElectroconvulsive therapy outcomeRating Scale scoresHigher MADRS scoresMagnetic resonance imagingECT outcomeOlder patientsIndex courseScale scoreResonance imagingTherapy outcomeFurther studiesScoresDepressionOutcomesPharmacotherapyPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply